Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.46 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.46 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.46 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.46 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.46 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | GPX4 | P36969 | 3/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1500553 | 0.98 | CYP2D6 (0.53) | CYP2D6CYP19A1GPX4SLC6A9CHRM2 | |
| SCHEMBL3298692 | 0.81 | MAPK1 (0.40) | CYP2D6CYP19A1GPX4SLC6A9CHRM2 | |
| SCHEMBL3296318 | 0.80 | OPRD1 (0.52) | GPX4SLC6A9TSHRMGLLOPRM1 | |
| SCHEMBL3296323 | 0.80 | OPRD1 (0.52) | GPX4SLC6A9TSHRMGLLOPRM1 | |
| SCHEMBL3299076 | 0.79 | OPRM1 (0.42) | CYP2D6CYP19A1GPX4SLC6A9CHRM2 | |
| SCHEMBL1500704 | 0.78 | MGLL (0.42) | CYP2D6CYP19A1GPX4CHRM2HTR1A | |
| SCHEMBL1500702 | 0.78 | MGLL (0.42) | CYP2D6CYP19A1GPX4CHRM2HTR1A | |
| SCHEMBL62801 | 0.77 | KMT2A (0.50) | CYP2D6CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL3349152 | 0.73 | CYP19A1 (0.43) | CYP2D6CYP19A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2911919 | 0.72 | CYP19A1 (0.57) | CYP2D6CYP19A1GPX4SLC6A9CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741316-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2010-06-22 | — | — | US | disclosed |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6872717-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ACHARD DANIEL (FR) | 2003-03-20 | — | — | US | disclosed |
| US-6479479-B2 | 1-DIARYLMETHYL-4-ALKYL OR ALKYLSULFONYLALKYL-AZETIDINES; CANNABINOID RECEPTOR ANTAGONISTS; NERVOUS SYSTEM DISORDERS (CNS); CARDIOVASCULAR AND GLANDULAR DISORDERS; DRUG ABUSE; PSYCHOLOGICAL DISORDERS; | AVENTIS PHARMA S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | CHRM2 107/4885HTR1A 238/4885ADRA2A 41/4885 |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | CHRM2 107/4885HTR1A 238/4885ADRA2A 41/4885 |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | CHRM2, ACHE, DRD2 | CHRM2 1/4885HTR1A 200/4885ADRA2A 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.